Metraipolis › archive › dc_38b287fb2166

Body Mass Index and Outcomes in HR+/HER2- Metastatic Breast Cancer Treated with Palbociclib: Insights from a National Real-World Study — Europe PMC PMID:42122175

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42122175
DOI
10.3390/cancers18091379
License (as archived)
solo-consultazione
Archived
2026-11-03T06:07:51.261Z
SHA-256 of the archived text
6f5b767b94635b1e42890b584d5b4ddfb13368cd852d5460a57b74f30d5e2f84
Stable URL of this page
https://metraipolis.com/documento/dc_38b287fb2166

How to cite

Body Mass Index and Outcomes in HR+/HER2- Metastatic Breast Cancer Treated with Palbociclib: Insights from a National Real-World Study — Europe PMC PMID:42122175 — Europe PMC (en), https://europepmc.org/article/MED/42122175 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_38b287fb2166 (Metraipolis archive dc_38b287fb2166, sha256 6f5b767b94635b1e42890b584d5b4ddfb13368cd852d5460a57b74f30d5e2f84)
BibTeX
@misc{dc38b287fb2166,
  title = {Body Mass Index and Outcomes in HR+/HER2- Metastatic Breast Cancer Treated with Palbociclib: Insights from a National Real-World Study — Europe PMC PMID:42122175},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42122175},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_38b287fb2166; sha256 6f5b767b94635b1e42890b584d5b4ddfb13368cd852d5460a57b74f30d5e2f84},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42122175. Agents can read the archived copy with the MCP tool read_document.